ILUMYA

This brand name is authorized in Australia, Israel, Japan, United States

Active ingredients

The drug ILUMYA contains one active pharmaceutical ingredient (API):

1 Tildrakizumab UNII DEW6X41BEK - TILDRAKIZUMAB

Tildrakizumab is a humanized IgG1/k monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin-23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines. Read about Tildrakizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ILUMYA Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AC17		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11613F, 11616J
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8772
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999456G1025
Country: US	FDA, National Drug Code	Identifier(s): 47335-177